Research article · 1 Jan 2026
Conference abstractPublished 17 Aug 2015
Updates on chronic Hepatitis B: Initiation of medical therapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Hepatitis B virus (HBV) infection is a global epidemic with estimated mortality 0.5-1.2 million deaths a year. Long-term goal of treatment on patients with chronic hepatitis B infection (CHB) is to reduce cirrhosis, hepatocellular carcinoma, and ultimately improve survival.The decision on initiating viral therapy can be complex because not all the patients with CHB derive significant clinical benefits from current medical therapies. Elevated HBV DNA level is a strong independent risk predictor of liver-related disease outcomes. Up to date, many studies have demonstrated improved clinical outcomes with successful viral suppression in CHB patients.Hepatic disease activity, assessed by histology and less accurately by alanine aminotransferase (ALT), is another major decision-making factor on initiating anti-viral therapy in patients with CHB. As in immune tolerance phase of CHB, characterized by high HBV DNA level, normal ALT, and no/minimal hepatic inflammation, disease progression is negligible.Treatment on these patients is therefore unlikely to alter long-term clinical outcomes. However, close monitoring of ALT level is highly recommended during immune tolerant phase astransition to immune clearance phase may occur. Anti-viral therapy is often required during immune clearance phase due to rapid disease progression.In patients with low HBV DNA and normal ALT, as seen in inactive carrier, medical therapy is typically not beneficial in long-term out comes due to minimal risk of developing hepatic complications.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Gastrointestinal & Digestive System.
Case report · 11 Nov 2025
Bitter Guard: A Gut Wrenching Surprise
Research article · 18 Jun 2025
Ursodeoxycholic Acid Treatment of LPAC Presenting as Post Cholecystectomy Pain: Rationale and Design of a Randomised Trial
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Gastrointestinal & Digestive System
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Na Li”